`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`
`
`
`
`
`
`C.A. No. _________________
`
`
`
`))))))))))
`
`
`)
`)
`)
`)
`)
`)
`
`BOEHRINGER INGELHEIM
`PHARMACEUTICALS INC.,
`BOEHRINGER INGELHEIM
`INTERNATIONAL GMBH, and
`BOEHRINGER INGELHEIM
`CORPORATION,
`
`
`Plaintiffs,
`
`
`
`v.
`
`
`DR. REDDY’S LABORATORIES LTD.
`and DR. REDDY’S LABORATORIES,
`INC.,
`
`
`Defendants.
`
`
`
`
`
`COMPLAINT
`
`Plaintiffs Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International
`
`GmbH, and Boehringer Ingelheim Corporation, by their undersigned attorneys, for their Complaint
`
`against Defendants, Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc., hereby
`
`allege as follows:
`
`NATURE OF THE ACTION
`
`
`
`This is an action for patent infringement arising under the Food and Drug Laws and
`
`Patent Laws of the United States, Titles 21 and 35 of the United States Code, respectively, arising
`
`from Defendants’ submission of an Abbreviated New Drug Application (“ANDA”) to the Food
`
`and Drug Administration (“FDA”) seeking approval to manufacture and sell a generic version of
`
`Plaintiffs’ JARDIANCE® (empagliflozin) tablets prior to the expiration of United States Patent
`
`No. 11,090,323.
`
`
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 2 of 10 PageID #: 2
`
`
`
`THE PARTIES
`
`
`
`Plaintiff Boehringer Ingelheim Pharmaceuticals Inc. (“BIPI”) is a corporation
`
`organized and existing under the laws of the State of Delaware, having a principal place of business
`
`at 900 Ridgebury Rd., Ridgefield, CT 06877.
`
`
`
`Plaintiff Boehringer Ingelheim International GmbH (“BII”) is a private limited
`
`liability company organized and existing under the laws of Germany, having a principal place of
`
`business at Binger Strasse 173, 55216 Ingelheim, Germany.
`
`
`
`Plaintiff Boehringer Ingelheim Corporation (“BIC”) is a corporation organized and
`
`existing under the laws of Nevada, having a principal place of business at 900 Ridgebury Road,
`
`Ridgefield, CT, 06877.
`
`
`
`BIPI, BII, and BIC are collectively referred to hereinafter as “Boehringer” or
`
`“Plaintiffs.”
`
`
`
`On information and belief, Defendant Dr. Reddy’s Laboratories Ltd. (“DRL Ltd.”)
`
`is a corporation organized and existing under the laws of India, having a principal place of business
`
`at 8-2-337 Road No. 3, Banjara Hills, Hyderabad, 500034, India.
`
`
`
`On information and belief, DRL Ltd. controls and directs a wholly owned
`
`subsidiary in the United States named Dr. Reddy’s Laboratories, Inc. (“DRL Inc.”). DRL Inc. is
`
`a New Jersey corporation having a principal place of business at 107 College Road East, Princeton,
`
`New Jersey 08540.
`
`
`
`
`
`DRL Ltd. and DRL Inc. are collectively referred to hereinafter as “DRL.”
`
`On information and belief, DRL Ltd. is in the business of, among other things,
`
`developing, preparing, manufacturing, selling, marketing, and distributing generic drugs,
`
`including distributing, selling, and marketing generic drugs throughout the United States,
`
`2
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 3 of 10 PageID #: 3
`
`
`
`including within the state of Delaware, through its own actions and through the actions of its agents
`
`and subsidiaries, including DRL Inc., from which DRL Ltd. derives a substantial portion of its
`
`revenue.
`
`
`
`On information and belief, DRL Inc. acted in concert with DRL Ltd. to prepare and
`
`submit ANDA No. 212336 (the “DRL ANDA”) for DRL Ltd.’s 10 mg and 25 mg empagliflozin
`
`tablets (“DRL ANDA Products”), which was done at the direction of, under the control of, and for
`
`the direct benefit of DRL Ltd. Following FDA approval of the DRL ANDA, DRL Ltd. will
`
`manufacture and supply the approved generic products to DRL Inc., which will then market and
`
`sell the products throughout the United States at the direction, under the control, and for the direct
`
`benefit of DRL Ltd.
`
`JURISDICTION AND VENUE
`
`
`
`This action arises under the patent laws of the United States, 35 U.S.C. §§ 100 et
`
`seq., generally, and 35 U.S.C. § 271(e)(2), specifically, and this Court has jurisdiction over the
`
`subject matter of this action under 28 U.S.C. §§ 1331 and 1338(a).
`
`
`
`Venue is proper in this Court because, among other things, each Defendant is a
`
`foreign corporation or the agent of a foreign corporation not residing in any United States district
`
`and may be sued in any judicial district. 28 U.S.C. § 1391(c). Moreover, DRL has litigated
`
`previous Hatch-Waxman patent infringement disputes in the District of Delaware and has not
`
`contested venue in those cases. See, e.g., Boehringer Ingelheim Pharmaceuticals Inc. et al. v.
`
`Dr. Reddy’s Laboratories, Ltd. et al., C.A. No. 19-1495, D.I. 9 (D. Del. Sept. 4, 2019); Boehringer
`
`Ingelheim Pharmaceuticals Inc. et al. v. Dr. Reddy's Laboratories, Ltd. et al., C.A. No. 18-779,
`
`D.I. 12 (D. Del. Jan. 11, 2019); Novartis Pharmaceuticals Corporation v. Dr. Reddy’s
`
`Laboratories Inc. et al., C.A. No. 22-498, D.I. 12 (D. Del. May 10, 2022). Further, DRL did not
`
`3
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 4 of 10 PageID #: 4
`
`
`
`contest venue, and filed counterclaims, in this District in the prior case in which Boehringer filed
`
`a lawsuit against DRL arising from DRL’s submission of the DRL ANDA. See Boehringer,
`
`C.A. No. 19-1495, D.I. 9; Boehringer, C.A. No. 18-1779, D.I. 12.
`
`PERSONAL JURISDICTION OVER DRL LTD.
`
`Plaintiffs reallege paragraphs 1-12 as if fully set forth herein.
`
`On information and belief, DRL Ltd. develops, manufactures, and/or distributes
`
`
`
`
`
`generic drugs for sale and use throughout the United States, including in this judicial district.
`
`
`
`This Court has personal jurisdiction over DRL Ltd. because, inter alia, DRL Ltd.,
`
`on information and belief: (1) has substantial, continuous, and systematic contacts with this State,
`
`either directly or through at least one of its wholly-owned subsidiaries or agents; (2) intends to
`
`market, sell, and/or distribute DRL’s infringing ANDA Products to residents of this State upon
`
`approval of ANDA No. 212336, either directly or through at least one of its wholly-owned
`
`subsidiaries or agents; (3) makes its generic drug products available in this State; and (4) enjoys
`
`substantial income from sales of its generic pharmaceutical products in this State on its own and
`
`through DRL Inc.
`
`
`
`On information and belief, DRL Ltd. has not contested jurisdiction in Delaware in
`
`one or more prior cases arising out of the filing of its ANDAs, and it has filed counterclaims in
`
`such cases. See, e.g., Boehringer Ingelheim Pharmaceuticals Inc. et al. v. Dr. Reddy’s
`
`Laboratories, Ltd. et al., C.A. No. 19-1495, D.I. 9 (D. Del. Sept. 4, 2019); Boehringer Ingelheim
`
`Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, Ltd. et al., C.A. No. 18-1779, D.I. 12
`
`(D. Del. Jan. 11, 2019); Novartis Pharmaceuticals Corporation v. Dr. Reddy’s Laboratories Inc.
`
`et al., C.A. No. 22-498, D.I. 12 (D. Del. May 10, 2022).
`
`4
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 5 of 10 PageID #: 5
`
`
`
`
`
`Alternatively, to the extent the above facts do not establish personal jurisdiction
`
`over DRL Ltd., this Court may exercise jurisdiction over DRL Ltd. pursuant to Fed. R. Civ. P.
`
`4(k)(2) because: (a) Plaintiffs’ claims arise under federal law; (b) DRL Ltd. would be a foreign
`
`defendant not subject to personal jurisdiction in the courts of any State; and (c) DRL Ltd. has
`
`sufficient contacts with the United States as a whole, including, but not limited to, filing ANDAs
`
`with the FDA and manufacturing and selling generic pharmaceutical products that are distributed
`
`throughout the United States, such that this Court’s exercise of jurisdiction over DRL Ltd. satisfies
`
`due process.
`
`
`
`
`
`PERSONAL JURISDICTION OVER DRL INC.
`
`Plaintiffs reallege paragraphs 1-17 as if fully set forth herein.
`
`On information and belief, DRL Inc. develops, manufactures, and/or distributes
`
`generic drugs for sale and use throughout the United States, including in this judicial district.
`
`
`
`This Court has personal jurisdiction over DRL Inc. because, inter alia, DRL Inc.,
`
`on information and belief: (1) intends to market, sell, or distribute DRL’s infringing ANDA
`
`Products to residents of this State; (2) is controlled by Defendant DRL Ltd. and is acting on behalf
`
`of DRL Ltd. with respect to the DRL ANDA; (3) makes its generic drug products available in this
`
`State; and (4) enjoys substantial income from sales of its generic pharmaceutical products in this
`
`State.
`
`
`
`On information and belief, DRL Inc. has not contested jurisdiction in Delaware in
`
`one or more prior cases arising out of the filing of its ANDAs, and it has filed counterclaims in
`
`such cases. See, e.g., Boehringer Ingelheim Pharmaceuticals Inc. et al. v. Dr. Reddy’s
`
`Laboratories, Ltd. et al., C.A. No. 19-1495, D.I. 9 (D. Del. Sept. 4, 2019); Boehringer Ingelheim
`
`Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, Ltd. et al., C.A. No. 18-1779, D.I. 12
`
`5
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 6 of 10 PageID #: 6
`
`
`
`(D. Del. Jan. 11, 2019); Novartis Pharmaceuticals Corporation v. Dr. Reddy’s Laboratories Inc.
`
`et al., C.A. No. 22-498, D.I. 12 (D. Del. May 10, 2022).
`
`BACKGROUND
`
`U.S. PATENT NO. 11,090,323
`
`
`
`On August 17, 2021, the USPTO duly and legally issued United States Patent
`
`No. 11,090,323 (“the ’323 patent”) entitled “Pharmaceutical composition, methods for treating
`
`and uses thereof” to inventors Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, and
`
`Hans-Juergen Woerle. A true and correct copy of the ’323 patent is attached as Exhibit A. The
`
`’323 patent is assigned to BII. BIC and BIPI are licensees of the ’323 patent.
`
`JARDIANCE®
`
`
`
`BIPI is the holder of New Drug Application (“NDA”) No. 204629 for
`
`empagliflozin, for oral use, in 10 mg and 25 mg dosages, which is sold under the trade name
`
`JARDIANCE®.
`
`
`
`Pursuant to 21 U.S.C. § 355(b)(1), and attendant FDA regulations, the ’323 patent
`
`is among the patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence
`
`Evaluations database (“Orange Book”) with respect to JARDIANCE®.
`
`
`
`The ’323 patent covers the JARDIANCE® product and its use.
`
`ACTS GIVING RISE TO THIS ACTION
`
`COUNT I—INFRINGEMENT OF THE ’323 PATENT AS TO THE DRL ANDA
`
`
`
`
`
`Plaintiffs reallege paragraphs 1-25 as if fully set forth herein.
`
`On information and belief, DRL submitted the DRL ANDA to the FDA, pursuant
`
`to 21 U.S.C. § 355(j), seeking approval to market the DRL ANDA Products.
`
`6
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 7 of 10 PageID #: 7
`
`
`
`
`
`DRL has represented that the DRL ANDA refers to and relies upon the
`
`JARDIANCE® NDA and contains data that, according to DRL, demonstrate the bioavailability or
`
`bioequivalence of the DRL ANDA Products to JARDIANCE®.
`
`
`
`Plaintiffs received a letter from DRL on or about July 21, 2022 stating that DRL
`
`was amending its ANDA to include a certification in the DRL ANDA, pursuant to 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), that, inter alia, certain claims of the ’323 patent are either invalid or will
`
`not be infringed by the commercial manufacture, use, or sale of the DRL ANDA Products (the
`
`“DRL Paragraph IV Certification”). DRL intends to engage in the commercial manufacture, use,
`
`offer for sale, and/or sale of the DRL ANDA Products prior to the expiration of the ’323 patent.
`
`
`
`DRL has infringed at least one claim of the ’323 patent, pursuant to 35 U.S.C.
`
`§ 271(e)(2)(A), by submitting, or causing to be submitted the DRL ANDA, by which DRL seeks
`
`approval from the FDA to engage in the manufacture, use, offer to sell, sale, or importation of the
`
`DRL ANDA Products prior to the expiration of the ’323 patent.
`
`
`
`DRL has declared its intent to manufacture, use, offer to sell, or sell in the United
`
`States or to import into the United States, the DRL ANDA Products in the event that the FDA
`
`approves the DRL ANDA. Accordingly, an actual and immediate controversy exists regarding
`
`DRL’s infringement of the ’323 patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`DRL’s manufacture, use, offer to sell, or sale of the DRL ANDA Products in the
`
`United States or importation of the DRL ANDA Products into the United States during the term
`
`of the ’323 patent would further infringe at least one claim of the ’323 patent under 35 U.S.C.
`
`§§ 271 (a), (b), and/or (c).
`
`7
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 8 of 10 PageID #: 8
`
`
`
`
`
`On information and belief, the DRL ANDA Products, when offered for sale, sold,
`
`and/or imported, and when used as directed, would be used in a manner that would directly infringe
`
`at least one of the claims of the ’323 patent either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the use of the DRL ANDA Products constitutes a
`
`material part of at least one of the claims of the ’323 patent; DRL knows that its ANDA Products
`
`are especially made or adapted for use in infringing at least one of the claims of the ’323 patent,
`
`either literally or under the doctrine of equivalents; and its ANDA Products are not staple articles
`
`of commerce or commodities of commerce suitable for substantial noninfringing use.
`
`
`
`On information and belief, the offering to sell, sale, and/or importation of the DRL
`
`ANDA Products would contributorily infringe at least one of the claims of the ’323 patent, either
`
`literally or under the doctrine of equivalents.
`
`
`
`On information and belief, DRL had knowledge of the ’323 patent and, by its
`
`promotional activities and package inserts for its ANDA Products, knows or should know that it
`
`will aid and abet another’s direct infringement of at least one of the claims of the ’323 patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the offering to sell, sale, and/or importation of the DRL
`
`ANDA Products by DRL would actively induce infringement of at least one of the claims of the
`
`’323 patent, either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, DRL does not deny that the DRL ANDA Products will
`
`infringe the claims of the ’323 patent. In the DRL Paragraph IV Certification, DRL did not deny
`
`that the DRL ANDA Products will infringe the claims of the ’323 patent.
`
`
`
`Plaintiffs will be substantially and irreparably harmed if DRL is not enjoined from
`
`infringing the ’323 patent.
`
`8
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 9 of 10 PageID #: 9
`
`
`
`
`
`This is an exceptional case within the meaning of 35 U.S.C. § 285, which warrants
`
`reimbursement of Boehringer’s reasonable attorney fees.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiffs respectfully request that the Court enter judgment against DRL
`
`and for the following relief:
`
`a.
`
`b.
`
`A Judgment be entered that DRL has infringed at least one claim of the ’323 patent
`
`by submitting the DRL ANDA;
`
`That DRL, its officers, agents, servants, employees, and those persons acting in
`
`active concert or participation with all or any of them be preliminarily and
`
`permanently enjoined from: (i) engaging in the commercial manufacture, use, offer
`
`to sell, or sale within the United States, or importation into the United States, of
`
`drugs or methods of administering drugs claimed in the ’323 patent, and
`
`(ii) seeking, obtaining, or maintaining approval of the DRL ANDA until the
`
`expiration of the ’323 patent or such other later time as the Court may determine;
`
`c.
`
`A judgment ordering that pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date
`
`of any approval of DRL’s ANDA under § 505(j) of the Federal Food, Drug and
`
`Cosmetic Act (21 U.S.C. § 355(j)) shall not be earlier than the expiration date of
`
`the ’323 patent, including any extensions;
`
`d.
`
`That Boehringer be awarded monetary relief if DRL commercially uses, offers to
`
`sell, or sells its proposed generic versions of JARDIANCE® or any other product
`
`that infringes or induces or contributes to the infringement of the ’323 patent, within
`
`the United States, prior to the expiration of this patent, including any extensions,
`
`and that any such monetary relief be awarded to Boehringer with prejudgment
`
`interest;
`
`9
`
`
`
`
`
`
`
`
`
`Case 1:22-cv-01102-UNA Document 1 Filed 08/22/22 Page 10 of 10 PageID #: 10
`
`e.
`
`f.
`
`g.
`
`A Judgment be entered that this case is exceptional, and that Plaintiffs are entitled
`
`to their reasonable attorneys’ fees pursuant to 35 U.S.C. § 285;
`
`Costs and expenses in this action; and
`
`Such other and further relief as the Court deems just and appropriate.
`
`
`
`
`
`
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`/s/ Megan E. Dellinger
`
`
`
`
`Jack B. Blumenfeld (#1014)
`Brian P. Egan (#6227)
`Megan E. Dellinger (#5739)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`began@morrisnichols.com
`mdellinger@morrisnichols.com
`
`Attorneys for Plaintiffs
`
`
`
`
`
`OF COUNSEL:
`
`Jeanna M. Wacker
`Sam Kwon
`Ashley L.B. Ross
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue
`New York, NY 10022
`(212) 446-4679
`
`James F. Hurst
`Bryan S. Hales
`KIRKLAND & ELLIS LLP
`300 North LaSalle
`Chicago, IL 60654
`(312) 862-2000
`
`August 22, 2022
`
`10
`
`